Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q3 2025 value amounting to $3.8 million.

  • ARS Pharmaceuticals' Other Non-Current Liabilities changed N/A to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year change of. This contributed to the annual value of $83000.0 for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Other Non-Current Liabilities is $3.8 million.
  • In the past 5 years, ARS Pharmaceuticals' Other Non-Current Liabilities registered a high of $3.8 million during Q3 2025, and its lowest value of $83000.0 during Q4 2021.